Search Results
Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer
Trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel metastatic HER2+ breast cancer
Treatment strategies for HER2+ metastatic breast cancer
Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer
#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer
Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancer
Improved IDFS for breast cancer patients who received trastuzumab emtansine
Trastuzumab Deruxtecan in HER2+ Breast Cancer
Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers
Optimizing Therapy in HER2+ Disease with Dr. Reshma Mahtani
Case Review: T-DM1 for Residual HER2+ Breast Cancer
Dr. Sanft on Treatment Options in HER2-Positive Breast Cancer
